Clinical parameters of CLL patients and in vitro cellular sensitivity to F-ara-A
Patient no. . | Age, y . | RAI . | Prior treatment . | Refractory . | IC50 F-ara-A . | % 17p deletion . |
|---|---|---|---|---|---|---|
| 1 | 47 | 4 | No | N/A | 6.6 | ND |
| 2 | 72 | 2 | No | N/A | 6.6 | NEG |
| 3 | 55 | 1 | No | N/A | 4.9 | NEG |
| 4 | 59 | 2 | No | N/A | 29.8 | 83.5 |
| 5 | 56 | 1 | No | N/A | 0.76 | ND |
| 6 | 56 | 1 | No | N/A | 0.91 | NEG |
| 7 | 65 | 1 | No | N/A | 0.29 | NEG |
| 8 | 44 | 4 | No | N/A | 2.06 | ND |
| 9 | 69 | 2 | No | N/A | 0.25 | NEG |
| 10 | 77 | 0 | FCR | No | 0.93 | ND |
| 11 | 68 | 2 | FCR | No | 8.90 | 18 |
| 12 | 68 | 4 | FAMP | No | 8.20 | ND |
| 13 | 62 | 4 | FCR | No | 0.84 | NEG |
| 14 | 60 | 3 | FCR | No | 3.54 | NEG |
| 15 | 32 | 0 | FCR | No | 0.85 | NEG |
| 16 | 61 | 4 | FAMP | Yes | > 30 | ND |
| 17 | 71 | 4 | FAMP | Yes | > 30 | 52.5 |
| 18 | 69 | 1 | FCR | Yes | > 30 | 78.5 |
| 19 | 70 | 4 | FAMP | Yes | > 30 | 85.5 |
| 20 | 56 | 1 | BMT, FAMP | Yes | 21.8 | 15.5 |
| 21 | 51 | 3 | CFAR | Yes | > 30 | 62.5 |
| 22 | 44 | 4 | FCR | Yes | > 30 | NEG |
| 23 | 54 | 1 | FCR | Yes | > 30 | ND |
| 24 | 74 | 1 | FC | Yes | 10.0 | ND |
| 25 | 80 | 2 | FAMP | Yes | > 30 | NEG |
| 26 | 72 | 4 | FND, FC, ESHAP, A, RIT | Yes | 23.2 | ND |
| 27 | 57 | 1 | FAMP, RIT | Yes | 30.0 | 9 |
| 28 | 69 | 3 | FR, BMT, CL | Yes | > 30 | ND |
| 29 | 61 | 4 | F, C, M, RIT, A, G | Yes | > 30 | NEG |
| 30 | 74 | 4 | FCR | Yes | > 30 | 77.5 |
Patient no. . | Age, y . | RAI . | Prior treatment . | Refractory . | IC50 F-ara-A . | % 17p deletion . |
|---|---|---|---|---|---|---|
| 1 | 47 | 4 | No | N/A | 6.6 | ND |
| 2 | 72 | 2 | No | N/A | 6.6 | NEG |
| 3 | 55 | 1 | No | N/A | 4.9 | NEG |
| 4 | 59 | 2 | No | N/A | 29.8 | 83.5 |
| 5 | 56 | 1 | No | N/A | 0.76 | ND |
| 6 | 56 | 1 | No | N/A | 0.91 | NEG |
| 7 | 65 | 1 | No | N/A | 0.29 | NEG |
| 8 | 44 | 4 | No | N/A | 2.06 | ND |
| 9 | 69 | 2 | No | N/A | 0.25 | NEG |
| 10 | 77 | 0 | FCR | No | 0.93 | ND |
| 11 | 68 | 2 | FCR | No | 8.90 | 18 |
| 12 | 68 | 4 | FAMP | No | 8.20 | ND |
| 13 | 62 | 4 | FCR | No | 0.84 | NEG |
| 14 | 60 | 3 | FCR | No | 3.54 | NEG |
| 15 | 32 | 0 | FCR | No | 0.85 | NEG |
| 16 | 61 | 4 | FAMP | Yes | > 30 | ND |
| 17 | 71 | 4 | FAMP | Yes | > 30 | 52.5 |
| 18 | 69 | 1 | FCR | Yes | > 30 | 78.5 |
| 19 | 70 | 4 | FAMP | Yes | > 30 | 85.5 |
| 20 | 56 | 1 | BMT, FAMP | Yes | 21.8 | 15.5 |
| 21 | 51 | 3 | CFAR | Yes | > 30 | 62.5 |
| 22 | 44 | 4 | FCR | Yes | > 30 | NEG |
| 23 | 54 | 1 | FCR | Yes | > 30 | ND |
| 24 | 74 | 1 | FC | Yes | 10.0 | ND |
| 25 | 80 | 2 | FAMP | Yes | > 30 | NEG |
| 26 | 72 | 4 | FND, FC, ESHAP, A, RIT | Yes | 23.2 | ND |
| 27 | 57 | 1 | FAMP, RIT | Yes | 30.0 | 9 |
| 28 | 69 | 3 | FR, BMT, CL | Yes | > 30 | ND |
| 29 | 61 | 4 | F, C, M, RIT, A, G | Yes | > 30 | NEG |
| 30 | 74 | 4 | FCR | Yes | > 30 | 77.5 |
IC50 values for F-ara-A (fludarabine) were determined by MTT assay as described in “Patients, materials, and methods.”
RAI indicates disease stage; N/A, not applicable; ND, not determined; NEG, negative for TP53 deletion; FCR, fludarabine, cyclophosphamide, and rituximab; FAMP, fludarabine; BMT, bone marrow transplantation; CFAR, cyclophosphamide, fludarabine, alemtuzumab, and rituximab; FC, fludarabine and cyclophosphamide; FND, fludarabine, mitoxantrone, dexamethasone; ESHAP, etoposide, methylpredniylosolone, cisplatin, and cytarabine; A, alemtuzumab; RIT, rituximab; CL, clofarabine; F, fludarabine; C, cyclophosphamide; M, mitoxantrone; and G, Geminex.